Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of “Buy” by Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has received an average rating of “Buy” from the seven brokerages that are presently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $6.33.

CNTX has been the subject of several research reports. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research note on Wednesday, January 15th. Finally, JMP Securities assumed coverage on Context Therapeutics in a research report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 target price for the company.

Hedge Funds Weigh In On Context Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Shay Capital LLC acquired a new stake in shares of Context Therapeutics during the fourth quarter valued at about $52,000. MPM Bioimpact LLC purchased a new position in Context Therapeutics in the fourth quarter valued at about $15,441,000. Millennium Management LLC grew its stake in Context Therapeutics by 24.2% during the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock valued at $188,000 after purchasing an additional 34,835 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Context Therapeutics during the 4th quarter worth approximately $31,000. Finally, Allostery Investments LP acquired a new position in shares of Context Therapeutics in the 4th quarter valued at approximately $998,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Stock Performance

CNTX opened at $0.84 on Thursday. Context Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.75. The firm has a 50 day moving average price of $0.97 and a 200 day moving average price of $1.64. The company has a market cap of $63.22 million, a PE ratio of -0.93 and a beta of 2.06.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.